Hormonal
Semaglutide, a long-acting GLP-1 receptor agonist, is hypothesized to reduce arterial stiffness (measured by carotid-femoral pulse wave velocity) and improve cardiometabolic markers in adults with type 1 diabetes.
This paper describes a planned clinical trial, not a finished treatment guideline. It suggests that semaglutide might help people with Type 1 Diabetes who are overweight and have heart risk factors by improving blood vessel stiffness. Patients should discuss this emerging research with their endocrinologist, as the results are not yet available.
We hypothesise that semaglutide will improve carotid femoral pulse wave velocity, and that the improvement will be mediated by changes in insulin resistance and postprandial hyperglucagonaemia.
Why this rating
This is a study protocol; no results are reported, only the hypothesis and methodology.
Source
Reducing cardiometabolic risk with semaglutide in type 1 diabetes (RESET1): Study protocol of a phase 2 double‐blinded randomised placebo‐controlled trial
Ruth Frampton et al. · Diabetic Medicine · 2024
DOI 10.1111/dme.15377
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →